reports
MOSL: SUN PHARMA (Buy)-Opportunity in Adversity-Multiple challenges in...
​SUN PHARMA: Opportunity in Adversity; Multiple challenges in FY18; recovery in earnings expected from FY19(SUNP IN, Mkt Cap USD20.0b, CMP INR539, TP INR650, 21% Upside, Buy)Sun Pharma (SUNP) is trading at ~16x FY19E PER, which is ~20% and 30% below its 10- and 5-year average valuations, respectively. The stock has corrected more than 50% from its peak of >INR1,100 (in April 2015). This downward movement can be attributed to the regulatory overhang on Halol, competition in key products, consol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.